www.xeljanz.com
Open in
urlscan Pro
2600:9000:2315:7e00:13:12cf:cf00:93a1
Public Scan
Submitted URL: https://www.xeljanzsupport.com/
Effective URL: https://www.xeljanz.com/sign-up?src_code=XELI11003611&utm_source=pfizer&utm_medium=vanity&utm_campaign=inoffice&utm_term...
Submission: On March 02 via automatic, source certstream-suspicious — Scanned from DE
Effective URL: https://www.xeljanz.com/sign-up?src_code=XELI11003611&utm_source=pfizer&utm_medium=vanity&utm_campaign=inoffice&utm_term...
Submission: On March 02 via automatic, source certstream-suspicious — Scanned from DE
Form analysis 1 forms found in the DOM
Name: sign-up — POST
<form id="signupForm" name="sign-up" method="POST" class="formWrapper" onsubmit="return ValidationFormSubmit('signup')" novalidate="" data-hj-suppress="">
<div class="step-1">
<div class="main-container-inner-2">
<div class="container-fluid">
<div class="tech-error-msg">
<h6>We're sorry.</h6>
<p>A temporary technical issue prevents us from bringing you the information you requested. Please try again later. Need additional assistance? Please <a href="/contact-us">contact us</a>.</p>
</div>
<div class="form-group">
<div class="formFieldsTitle">
<p><strong>All fields are required unless marked optional.</strong></p>
</div>
</div>
</div>
<div class="container-fluid">
<div class="row">
<div class="col-md-6 col-sm-6">
<div class="form-group">
<div class="position-relative">
<label for="first_name">First Name</label>
<input type="text" maxlength="50" class="form-control validate validateicon step_1" name="first_name" id="first_name" value="" autocomplete="off" required="">
</div>
</div>
</div>
<div class="col-md-6 col-sm-6">
<div class="form-group">
<div class="position-relative">
<label for="last_name">Last Name</label>
<input type="text" maxlength="50" class="form-control validate validateicon step_1" name="last_name" id="last_name" value="" autocomplete="off" required="">
</div>
</div>
</div>
</div>
</div>
<div class="container-fluid">
<div class="row">
<div class="col-md-6 col-sm-6">
<div class="form-group">
<div class="position-relative">
<label for="email">Email</label>
<input type="text" maxlength="50" class="form-control validate validateicon step_1" name="email" id="email" autocomplete="off" required="">
</div>
</div>
</div>
</div>
</div>
<div class="container-fluid">
<div class="formFieldsTitle pt-3">
<p>Have you already been prescribed XELJANZ?</p>
</div>
</div>
<div class="d-block">
<div class="col-sm-6 col-md-4">
<div class="row">
<div class="col-6 col-sm-6">
<div class="formButton btn-form">
<input type="radio" name="indOptoinYN" id="patient_stream" value="Yes">
<label for="patient_stream"><span>Yes</span></label>
</div>
</div>
<div class="col-6 col-sm-6">
<div class="formButton btn-form">
<input type="radio" name="indOptoinYN" id="info_seeker" value="No">
<label for="info_seeker"><span>No</span></label>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="main-container">
<div class="pb-5">
<div class="container-fluid">
<div class="row">
<div class="col-sm-12 pt-5 pb-5">
<div class="content-divider"></div>
</div>
</div>
</div>
<div class="container-fluid pt-2" id="stepper">
<div class="row">
<div class="col-sm-8 offset-sm-2">
<div class="formProgressbarWrap pb-3">
<div class="formProgressbar">
<ul>
<li class="active">Step 1</li>
<li class="">Step 2</li>
<li class="">Done</li>
</ul>
</div>
</div>
</div>
</div>
</div>
<div class="container-fluid">
<div class="row">
<div class="col-sm-8 offset-sm-2">
<div class="formProgressbarText text-center">
<p>Please complete the above selections for treatment indication, name, email, and current prescription status to complete sign-up form.</p>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="indOptoinYN_section">
<div class="main-container-inner-2">
<div class="container-fluid">
<div class="formFieldsTitle pb-3">
<p><strong>All fields are required unless marked optional.</strong></p>
</div>
</div>
<div class="container-fluid">
<div class="formFieldsTitle">
<div class="hideAll ra_yes psa_yes uc_yes">
<p>Approximately when did you start treatment with XELJANZ?</p>
</div>
<div class="hideAll ra_no">
<p>Approximately when is your next doctor’s appointment?</p>
</div>
<div class="hideAll psa_no">
<p>Approximately when is your next doctor’s appointment?</p>
</div>
<div class="hideAll uc_no">
<p>Have you already tried certain medicines, and are you interested in discussing available prescription treatment options with your doctor?</p>
</div>
</div>
</div>
</div>
<div class="hideAll ra_yes">
<div class="main-container-inner-2">
<div class="container-fluid">
<div class="pb-3">
<div class="formRadio">
<div class="form-group d-table">
<div class="float-left">
<input class="step_2" type="radio" name="start_treatment_ra_yes" id="start_treatment_ra_yes" value="Yes" required="">
<label for="start_treatment_ra_yes">
<div></div>
</label>
</div>
<div class="float-left pt-2">
<div class="position-relative">
<div>
<input type="text" maxlength="50" inputmode="none" class="form-control form-calendar validate validateicon step_2" name="start_treatment_date" id="start_treatment_date" placeholder="MM/DD/YYYY" autocomplete="nope">
</div>
</div>
</div>
</div>
<div class="form-group">
<input class="step_2" type="radio" name="start_treatment_ra_yes" id="start_treatment_ra_yes_dont" value="I have not started yet/I don't know" required="">
<label for="start_treatment_ra_yes_dont">
<div>I have not started yet/I don’t know</div>
</label>
</div>
</div>
</div>
</div>
</div>
<div class="main-container-inner-2">
<div class="container-fluid">
<div class="formFieldsTitle">
<div>
<p>Approximately when is your next doctor’s appointment?</p>
</div>
</div>
</div>
<div class="container-fluid">
<div class="pb-4">
<div class="formRadio">
<div class="form-group d-table">
<div class="float-left">
<input class="step_2" type="radio" name="ra_yes_next_doctor_appointment" id="ra_yea_next_doctor_appointment" value="Yes" required="">
<label for="ra_yea_next_doctor_appointment"></label>
</div>
<div class="float-left pt-2">
<div class="position-relative">
<div>
<input type="text" maxlength="50" inputmode="none" class="form-control form-calendar validate validateicon step_2" name="next_doctor_appointment_date" id="next_doctor_appointment_date" placeholder="MM/DD/YYYY"
autocomplete="nope">
</div>
</div>
</div>
</div>
<div class="form-group">
<input class="step_2" type="radio" name="ra_yes_next_doctor_appointment" id="ra_yea_next_doctor_appointment_no" value="I don’t know/Not scheduled at this time" required="">
<label for="ra_yea_next_doctor_appointment_no">I don’t know</label>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="hideAll psa_yes">
<div class="main-container-inner-2">
<div class="container-fluid">
<div class="pb-3">
<div class="formRadio">
<div class="form-group d-table">
<div class="float-left">
<input class="step_2" type="radio" name="psa_yes_start_treatment" id="psa_yes_start_treatment" value="Yes" required="">
<label for="psa_yes_start_treatment">
<div></div>
</label>
</div>
<div class="float-left pt-2">
<div class="position-relative">
<div>
<input type="text" maxlength="50" inputmode="none" class="form-control form-calendar validate validateicon step_2" name="psa_yes_start_treatment_date" id="psa_yes_start_treatment_date" placeholder="MM/DD/YYYY"
autocomplete="nope">
</div>
</div>
</div>
</div>
<div class="form-group">
<input class="step_2" type="radio" name="psa_yes_start_treatment" id="psa_yes_not_started" value="I have not started yet/I don't know" required="">
<label for="psa_yes_not_started">
<div>I have not started yet/I don’t know</div>
</label>
</div>
</div>
</div>
</div>
</div>
<div class="main-container-inner-2">
<div class="container-fluid">
<div class="formFieldsTitle">
<div>
<p>Approximately when is your next doctor’s appointment?</p>
</div>
</div>
</div>
<div class="container-fluid">
<div class="pb-4">
<div class="formRadio">
<div class="form-group d-table">
<div class="float-left">
<input class="step_2" type="radio" name="psa_yes_next_doctor_appointment" id="psa_yes_next_doctor_appointment" value="Yes" required="">
<label for="psa_yes_next_doctor_appointment"></label>
</div>
<div class="float-left pt-2">
<div class="position-relative">
<div>
<input type="text" maxlength="50" inputmode="none" class="form-control form-calendar validate validateicon step_2" name="psa_yes_next_doctor_appointment_date" id="psa_yes_next_doctor_appointment_date" placeholder="MM/DD/YYYY"
autocomplete="nope">
</div>
</div>
</div>
</div>
<div class="form-group">
<input class="step_2" type="radio" name="psa_yes_next_doctor_appointment" id="psa_yes_next_doctor_appointment_no" value="I don’t know/Not scheduled at this time" required="">
<label for="psa_yes_next_doctor_appointment_no">I don’t know</label>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="hideAll uc_yes">
<div class="main-container-inner-2">
<div class="container-fluid">
<div class="pb-3">
<div class="formRadio">
<div class="form-group d-table">
<div class="float-left">
<input class="step_2" type="radio" name="uc_yes_start_treatment" id="uc_yes_start_treatment" value="Yes" required="">
<label for="uc_yes_start_treatment">
<div></div>
</label>
</div>
<div class="float-left pt-2">
<div class="position-relative">
<div>
<input type="text" maxlength="50" inputmode="none" class="form-control form-calendar validate validateicon step_2" name="uc_yes_start_treatment_date" id="uc_yes_start_treatment_date" placeholder="MM/DD/YYYY" autocomplete="nope">
</div>
</div>
</div>
</div>
<div class="form-group">
<input class="step_2" type="radio" name="uc_yes_start_treatment" id="uc_yes_not_started" value="I have not started yet/I don't know" required="">
<label for="uc_yes_not_started">
<div>I have not started yet/I don’t know</div>
</label>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="hideAll ra_no">
<div class="main-container-inner-2">
<div class="container-fluid">
<div class="formRadio">
<div class="form-group d-table">
<div class="float-left">
<input class="step_2" type="radio" name="ra_no_start_treatment" id="ra_no_start_treatment" value="Yes" required="">
<label for="ra_no_start_treatment"></label>
</div>
<div class="float-left pt-2">
<div class="position-relative">
<div>
<input type="text" maxlength="50" inputmode="none" class="form-control form-calendar validate validateicon step_2" name="ra_no_start_treatment_date" id="ra_no_start_treatment_date" placeholder="MM/DD/YYYY" autocomplete="nope">
</div>
</div>
</div>
</div>
<div class="form-group">
<input class="step_2" type="radio" name="ra_no_start_treatment" id="ra_no_not_started" value="I don’t know/Not scheduled at this time" required="">
<label for="ra_no_not_started">
<div>I don’t know</div>
</label>
</div>
</div>
</div>
</div>
</div>
<div class="hideAll psa_no">
<div class="main-container-inner-2">
<div class="container-fluid">
<div class="formRadio">
<div class="form-group d-table">
<div class="float-left">
<input class="step_2" type="radio" name="psa_no_start_treatment" id="psa_no_start_treatment" value="Yes" required="">
<label for="psa_no_start_treatment"></label>
</div>
<div class="float-left pt-2">
<div class="position-relative">
<div>
<input type="text" maxlength="50" inputmode="none" class="form-control form-calendar validate validateicon step_2" name="psa_no_start_treatment_date" id="psa_no_start_treatment_date" placeholder="MM/DD/YYYY" autocomplete="nope">
</div>
</div>
</div>
</div>
<div class="form-group">
<input class="step_2" type="radio" name="psa_no_start_treatment" id="psa_no_not_started" value="I don’t know/Not scheduled at this time" required="">
<label for="psa_no_not_started">
<div>I don’t know</div>
</label>
</div>
</div>
</div>
</div>
</div>
<div class="hideAll uc_no">
<div class="main-container-inner-2">
<div class="container-fluid">
<div class="formRadio">
<div class="form-group d-table">
<div class="float-left">
<input class="step_2" type="radio" name="uc_no_start_treatment" id="uc_no_start_treatment" value="Yes" required="">
<label for="uc_no_start_treatment">
<div>Yes</div>
</label>
</div>
</div>
<div class="form-group">
<input class="step_2" type="radio" name="uc_no_start_treatment" id="uc_no_not_started" value="No" required="">
<label for="uc_no_not_started">
<div>No</div>
</label>
</div>
</div>
</div>
</div>
</div>
<div class="hideAll ra_no psa_no uc_no">
<div class="main-container-inner-2">
<div class="container-fluid">
<div class="formFieldsTitle">
<div class="hideAll ra_no">
<p>How are you currently treating your rheumatoid arthritis? <span>- Optional</span></p>
</div>
<div class="hideAll psa_no">
<p>How are you currently treating your active psoriatic arthritis? <span>- Optional</span></p>
</div>
<div class="hideAll uc_no">
<p>How are you currently treating your ulcerative colitis? <span>– Optional</span></p>
</div>
</div>
</div>
<div class="container-fluid">
<div class="pb-4">
<div class="formRadio">
<div class="form-group">
<div>
<input type="radio" name="currently_treating" id="checked_pill" class="step_2" value="pill">
<label for="checked_pill">Pill</label>
</div>
</div>
<div class="form-group">
<div>
<input type="radio" name="currently_treating" id="checked_injection" class="step_2" value="injection">
<label for="checked_injection">Injection</label>
</div>
</div>
<div class="form-group">
<div>
<input type="radio" name="currently_treating" id="checked_infusion" class="step_2" value="infusion">
<label for="checked_infusion">Infusion</label>
</div>
</div>
<div class="form-group">
<div>
<input type="radio" name="currently_treating" id="checked_no" class="step_2" value="I don't know">
<label for="checked_no">I don’t know</label>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="pb-5">
<div class="formFullPanel">
<div class="main-container-inner-2">
<div class="formColomLeft">
<div class="formColomLeftInner">
<div class="py-4">
<div class="container-fluid">
<div class="formFieldsTitle pb-3">
<div class="hideAll ra_yes psa_yes">
<p>The XELJANZ+YOU Support Program provides tools and information to help you take an active role in your treatment with XELJANZ and better manage your disease. You’ll also receive resources in the mail.</p>
</div>
<div class="hideAll uc_yes">
<p>The XELJANZ+YOU Support Program provides tools and information to help you take an active role in your treatment with XELJANZ and better manage your disease. You’ll also receive a welcome kit in the mail.</p>
</div>
<div class="hideAll ra_no">
<p>By completing this registration, you’ll also receive resources in the mail to help you understand how RA may be impacting you. Materials include a welcome kit that features an informational brochure, spiral-bound RA journal,
and loop cloth assistance tool.</p>
</div>
<div class="hideAll psa_no">
<p>By completing this registration, you’ll also receive resources in the mail to help you understand how psoriatic arthritis may be impacting you. Materials include a welcome kit that features a psoriatic arthritis-friendly tote
bag, a psoriatic arthritis journal, a day-to-day symptom tracker, and a doctor discussion guide.</p>
</div>
<div class="hideAll uc_no">
<p>Continue this short registration to receive a welcome kit in the mail. This kit contains additional resources and information about XELJANZ and UC, so you can prepare for a productive conversation with your <nobr>
doctor. <span>– Optional</span></nobr>
</p>
</div>
</div>
</div>
<div class="container-fluid">
<div class="form-group">
<div class="position-relative">
<label for="address_1">Street Address 1</label>
<input type="text" maxlength="50" class="form-control validate validateicon step_2 pac-target-input" name="address_1" id="address_1" value="" autocomplete="off" placeholder="" required="">
</div>
</div>
</div>
<div class="container-fluid">
<div class="form-group">
<div class="position-relative">
<label for="address_2">Street Address 2 <span>- Optional</span></label>
<input type="text" maxlength="50" class="form-control optional" name="address_2" id="address_2" value="" autocomplete="nope">
</div>
</div>
</div>
<div class="container-fluid">
<div class="form-group">
<div class="position-relative">
<label for="city">City</label>
<input type="text" maxlength="50" class="form-control validate validateicon step_2" name="city" id="city" value="" autocomplete="nope" required="">
</div>
</div>
</div>
<div class="container-fluid">
<div class="row">
<div class="col-md-6 col-sm-6 col-6">
<div class="form-group">
<div class="position-relative">
<label for="selected_state">State</label>
<div class="formSelectbox">
<select class="form-control validate custom-select step_2" name="selected_state" id="selected_state" autocomplete="nope" required="">
<option value="">Select</option>
<option value="AL">Alabama</option>
<option value="AK">Alaska</option>
<option value="AZ">Arizona</option>
<option value="AR">Arkansas</option>
<option value="CA">California</option>
<option value="CO">Colorado</option>
<option value="CT">Connecticut</option>
<option value="DE">Delaware</option>
<option value="DC">District of Columbia</option>
<option value="FL">Florida</option>
<option value="GA">Georgia</option>
<option value="GU">Guam</option>
<option value="HI">Hawaii</option>
<option value="ID">Idaho</option>
<option value="IL">Illinois</option>
<option value="IN">Indiana</option>
<option value="IA">Iowa</option>
<option value="KS">Kansas</option>
<option value="KY">Kentucky</option>
<option value="LA">Louisiana</option>
<option value="ME">Maine</option>
<option value="MD">Maryland</option>
<option value="MA">Massachusetts</option>
<option value="MI">Michigan</option>
<option value="MN">Minnesota</option>
<option value="MS">Mississippi</option>
<option value="MO">Missouri</option>
<option value="MT">Montana</option>
<option value="NE">Nebraska</option>
<option value="NV">Nevada</option>
<option value="NH">New Hampshire</option>
<option value="NJ">New Jersey</option>
<option value="NM">New Mexico</option>
<option value="NY">New York</option>
<option value="NC">North Carolina</option>
<option value="ND">North Dakota</option>
<option value="OH">Ohio</option>
<option value="OK">Oklahoma</option>
<option value="OR">Oregon</option>
<option value="PA">Pennsylvania</option>
<option value="PR">Puerto Rico</option>
<option value="RI">Rhode Island</option>
<option value="SC">South Carolina</option>
<option value="SD">South Dakota</option>
<option value="TN">Tennessee</option>
<option value="TX">Texas</option>
<option value="VI">US Virgin Islands</option>
<option value="UT">Utah</option>
<option value="VT">Vermont</option>
<option value="VA">Virginia</option>
<option value="WA">Washington</option>
<option value="WV">West Virginia</option>
<option value="WI">Wisconsin</option>
<option value="WY">Wyoming</option>
</select>
</div>
</div>
</div>
</div>
<div class="col-md-6 col-sm-6 col-6">
<div class="form-group">
<div class="position-relative">
<label for="zip_code">ZIP Code</label>
<input type="tel" class="form-control validate validateicon custom-number step_2" name="zip_code" id="zip_code" value="" maxlength="5" autocomplete="nope" required="">
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="formColomRight">
<div class="formColomRightInner">
<div class="formImage">
<div class="hideAll ra_yes">
<div class="d-none d-sm-block">
<img class="" data-src="/images/form-patient-stream-ra-psa-uc-desktop.jpg" alt="XELJANZ+YOU LOGO" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7">
</div>
<div class="d-block d-sm-none">
<img class="" data-src="/images/form-patient-stream-ra-psa-uc-mobile.jpg" alt="XELJANZ+YOU LOGO" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7">
</div>
</div>
<div class="hideAll psa_yes">
<div class="d-none d-sm-block">
<img class="" data-src="/images/psa-large-patient-stream.jpg" alt="XELJANZ+YOU LOGO" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7">
</div>
<div class="d-block d-sm-none">
<img class="" data-src="/images/psa-small-patient-stream.jpg" alt="XELJANZ+YOU LOGO" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7">
</div>
</div>
<div class="hideAll uc_yes">
<div class="d-none d-sm-block">
<img class="" data-src="/images/uc-large-patient-stream.jpg" alt="XELJANZ+YOU LOGO" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7">
</div>
<div class="d-block d-sm-none">
<img class="" data-src="/images/uc-small-patient-stream.jpg" alt="XELJANZ+YOU LOGO" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7">
</div>
</div>
<div class="hideAll ra_no">
<div class="d-none d-sm-block">
<img class="" data-src="/images/form-info-seeker-ra-desktop.jpg" alt="XELJANZ+YOU LOGO" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7">
</div>
<div class="d-block d-sm-none">
<img class="" data-src="/images/form-info-seeker-ra-mobile.jpg" alt="XELJANZ+YOU LOGO" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7">
</div>
</div>
<div class="hideAll psa_no">
<div class="d-none d-sm-block">
<img class="" data-src="/images/form-info-seeker-psa-desktop.jpg" alt="XELJANZ+YOU LOGO" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7">
</div>
<div class="d-block d-sm-none">
<img class="" data-src="/images/form-info-seeker-psa-mobile.jpg" alt="XELJANZ+YOU LOGO" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7">
</div>
</div>
<div class="hideAll uc_no">
<div class="d-none d-sm-block">
<img class="" data-src="/images/form-info-seeker-uc-desktop.jpg" alt="XELJANZ+YOU LOGO" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7">
</div>
<div class="d-block d-sm-none">
<img class="" data-src="/images/form-info-seeker-uc-mobile.jpg" alt="XELJANZ+YOU LOGO" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7">
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="hideAll ra_yes psa_yes uc_yes">
<div class="main-container-inner-2 pb-5">
<div class="container-fluid">
<div class="bg-lightgray py-3">
<div class="container-fluid">
<div class="formFieldsTitle">
<p>PLEASE VERIFY THE FOLLOWING INFORMATION TO RECEIVE A CO-PAY SAVINGS CARD.</p>
</div>
<div class="pl-2 pb-2">
<div class="list-disc">
<ul>
<li>I do not have insurance from any federal healthcare program (including Medicare, Medicaid, TRICARE, or any other state or federal medical pharmaceutical benefit program or pharmaceutical assistance program).</li>
<li>I am not over 65 years of age and retired, and if applicable, neither is my partner.</li>
<li>I do not receive Social Security Disability or any other Social Security Administration benefit.</li>
<li>I am not active duty military, and if applicable, neither is an immediate family member.</li>
<li>I agree with the <a class="popupShow" href="#terms-conditions">limits, terms, and conditions</a> that apply.</li>
</ul>
</div>
</div>
<div class="formCheckbox">
<div class="position-relative">
<input type="checkbox" name="checked_agree" id="checked_agree" class="step_2" value="YES">
<label for="checked_agree"><strong>I meet the defined requirements.</strong></label>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="main-container-inner-2 pb-3">
<div class="container-fluid">
<div class="form-group">
<div class="formCheckbox">
<input type="checkbox" name="checked_age" id="checked_age" class="step_2" value="Yes" required="">
<label for="checked_age">By checking this box, I verify that I am age 18 or older.</label>
</div>
</div>
</div>
<div class="container-fluid">
<div class="form-group">
<div class="formCheckbox">
<input type="checkbox" name="checked_communication" id="checked_communication" class="step_2" value="Yes" required="">
<label for="checked_communication">
<div class="hideAll ra_yes ra_no">I agree to receive communications via email, social media channels, and materials in the mail from Pfizer or parties acting on its behalf containing helpful tools and information on XELJANZ and living
with rheumatoid arthritis.</div>
<div class="hideAll psa_yes psa_no">I agree to receive communications via email, social media channels, and materials in the mail from Pfizer or parties acting on its behalf containing helpful tools and information on XELJANZ and living
with psoriatic arthritis.</div>
<div class="hideAll uc_yes uc_no">I agree to receive communications via email, social media channels, and materials in the mail from Pfizer or parties acting on its behalf containing helpful tools and information on XELJANZ and living
with ulcerative colitis.</div>
</label>
</div>
</div>
</div>
</div>
<div id="recaptcha" class="g-recaptcha" data-sitekey="6Lf039wUAAAAAL7G4yFFUq7tny-QHwpiic1TxnMk" data-size="invisible" data-callback="onSubmitSignup">
<div class="grecaptcha-badge" data-style="bottomright"
style="width: 256px; height: 60px; display: block; transition: right 0.3s ease 0s; position: fixed; bottom: 14px; right: -186px; box-shadow: gray 0px 0px 5px; border-radius: 2px; overflow: hidden; visibility: hidden;">
<div class="grecaptcha-logo"><iframe title="reCAPTCHA"
src="https://www.google.com/recaptcha/api2/anchor?ar=1&k=6Lf039wUAAAAAL7G4yFFUq7tny-QHwpiic1TxnMk&co=aHR0cHM6Ly93d3cueGVsamFuei5jb206NDQz&hl=de&v=PdoyIVkd8v16xl_NMp3H0N1Y&size=invisible&cb=genmdxc0dc1j" width="256"
height="60" role="presentation" name="a-pmpagvasd1zz" frameborder="0" scrolling="no" sandbox="allow-forms allow-popups allow-same-origin allow-scripts allow-top-navigation allow-modals allow-popups-to-escape-sandbox"></iframe></div>
<div class="grecaptcha-error"></div><textarea id="g-recaptcha-response" name="g-recaptcha-response" class="g-recaptcha-response"
style="width: 250px; height: 40px; border: 1px solid rgb(193, 193, 193); margin: 10px 25px; padding: 0px; resize: none; display: none;"></textarea>
</div><iframe style="display: none;"></iframe>
</div>
<div class="main-container-inner-2 pb-5 signup-submit-wrapper">
<div class="container-fluid text-center">
<input type="submit" class="btn formButtonSubmit" value="Sign Up Now">
</div>
</div>
</div>
</form>Text Content
CLICK FOR IMPORTANT SAFETY UPDATE
IMPORTANT SAFETY UPDATE FOR XELJANZ® (TOFACITINIB)
On Friday, December 3, 2021, the U.S. Food and Drug Administration (FDA) updated
the XELJANZ full prescribing information. Pfizer issued a media statement
announcing that the U.S. full prescribing information for XELJANZ® (tofacitinib)
has been updated based on the U.S. FDA’s completed review of the ORAL
Surveillance trial, a post-marketing required safety study. Talk to your
healthcare provider if you have any questions or concerns about this safety
update. Your healthcare provider should consider the benefits and risks of
XELJANZ.
The safety information below applies to all marketed formulations of XELJANZ.
Specific risks associated with certain dosing are noted.
As a result of this review, an additional warning for Major Cardiovascular
Events, and updated warnings for Mortality, Cancer, and Blood Clots were
included in the Boxed Warning and related Warnings and Precautions section of
the prescribing information and in the Most Important Information I Should Know
section of the patient Medication Guide for XELJANZ.
The updated Boxed Warning information regarding Mortality discusses the
increased risk of death in people 50 years of age and older who have at least 1
heart disease (cardiovascular) risk factor taking recommended doses of XELJANZ.
The updated Boxed Warning regarding cancer discusses a higher risk of certain
cancers, including lymphoma and lung cancer in patients taking XELJANZ,
especially if you are a current or past smoker. Tell your healthcare provider if
you are a current or past smoker or have had any type of cancer.
The new Boxed Warning includes information regarding increased risk of major
cardiovascular events such as heart attack, stroke, or death in people 50 years
of age and older who have at least 1 heart disease (cardiovascular) risk factor
and are taking recommended doses of XELJANZ, especially if you are a current or
past smoker.
Patients taking XELJANZ should seek medical attention right away or get
emergency help if you have any symptoms of a heart attack or stroke, including:
* discomfort in the center of your chest that lasts for more than a few
minutes, or that goes away and comes back
* severe tightness, pain, pressure, or heaviness in your chest, throat, neck,
or jaw
* pain or discomfort in your arms, back, neck, jaw, or stomach
* shortness of breath with or without chest discomfort
* breaking out in a cold sweat
* nausea or vomiting
* feeling lightheaded
* weakness in one part or on one side of your body
* slurred speech
The updated Boxed Warning regarding blood clots in the lungs (pulmonary
embolism, PE), veins of the legs (deep vein thrombosis, DVT) and arteries
(arterial thrombosis) discusses that blood clots have happened more often in
patients who are 50 years of age and older and with at least 1 heart disease
(cardiovascular) risk factor taking recommended doses of XELJANZ. Patients
should tell their healthcare provider if they have had blood clots in the veins
of their legs, arms, or lungs or clots in arteries in the past. Patients should
always ask their doctors for medical advice about adverse events. You are
encouraged to report adverse events related to Pfizer products by calling
1-800-438-1985 (U.S. only). If you prefer, you may contact the U.S. Food and
Drug Administration (FDA) directly. Visit http://www.fda.gov/MedWatch or call
1-800-FDA-1088.
The FDA approved use of XELJANZ for adults with moderately to severely active
rheumatoid arthritis, active psoriatic arthritis, and for children age 2 and
over with polyarticular course juvenile idiopathic arthritis and now recommends
use after one or more medicines called tumor necrosis factor (TNF) blockers did
not work well or cannot be tolerated.
If you have any questions about these updates talk to your healthcare provider.
The updated Important Safety Information and Indications for XELJANZ are
included below for your review.
It is also important to read the patient Medication Guide you receive with your
XELJANZ prescriptions, which explains the important things you need to know
about the medicine. These include side effects, what the medicine is used for,
how to take and store it properly, and other things to watch for when you’re
taking the medicine.
Information about Post-Marketing Safety Study
When the FDA first approved XELJANZ for adults with moderate to severe
rheumatoid arthritis in 2012, the agency required a clinical safety trial to
examine the risk for heart-related problems, cancer, and serious infections in
XELJANZ compared to another type of medicine called tumor necrosis factor (TNF)
blockers. This trial, known as Oral Surveillance enrolled 4,369 participants who
were required to be at least 50 years of age and have at least one
cardiovascular risk factor.
IMPORTANT SAFETY INFORMATION
The safety information below applies to all marketed formulations of XELJANZ.
Specific risks associated with certain dosing are noted.
Serious infections. XELJANZ can lower the ability of your immune system to fight
infections. Do not start taking XELJANZ if you have any kind of infection unless
your healthcare provider tells you it is okay. Serious infections have happened
in people taking XELJANZ. These serious infections include tuberculosis (TB) and
infections caused by bacteria, fungi, or viruses that can spread throughout the
body. Some people have died from these infections. Your healthcare provider
should test you for TB before starting and during treatment with XELJANZ. You
should not start taking XELJANZ if you have any kind of infection unless your
healthcare professional tells you it is okay.
Before and after starting XELJANZ, tell your doctor if you have an infection or
symptoms of an infection, including:
* fever, sweating, or chills
* cough
* blood in phlegm
* warm, red, or painful skin or sores on your body
* burning when you urinate
* urinating more often than normal
* muscle aches
* shortness of breath
* weight loss
* diarrhea or stomach pain
* feeling very tired
Increased risk of death in people 50 years of age and older who have at least 1
heart disease (cardiovascular) risk factor and are taking XELJANZ 5 mg twice
daily or XELJANZ 10 mg twice daily.
Cancer. XELJANZ may increase your risk of certain cancers by changing the way
your immune system works. Lymphoma and other cancers, including skin cancers,
can happen. People taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily
have a higher risk of certain cancers including lymphoma and lung cancer,
especially if you are a current or past smoker. Tell your healthcare provider if
you have ever had any type of cancer.
Higher dose. People with ulcerative colitis taking the higher dose of XELJANZ
(10 mg twice daily) or XELJANZ XR (22 mg one time each day) have a higher risk
of serious infections, shingles, or skin cancers.
Immune system problem. Some people who have taken XELJANZ with certain other
medicines to prevent kidney transplant rejection have had a problem with certain
white blood cells growing out of control (Epstein Barr Virus–associated
post-transplant lymphoproliferative disorder).
Increased risk of major cardiovascular events such as heart attack, stroke or
death in people 50 years of age and older who have at least 1 heart disease
(cardiovascular) risk factor and are taking XELJANZ 5 mg twice daily or
XELJANZ 10 mg twice daily, especially if you are a current or past smoker.
Get emergency help right away if you have any symptoms of a heart attack or
stroke while taking XELJANZ, including:
* discomfort in the center of your chest that lasts for more than a few
minutes, or that goes away and comes back
* severe tightness, pain, pressure, or heaviness in your chest, throat, neck,
or jaw
* pain or discomfort in your arms, back, neck, jaw, or stomach
* shortness of breath with or without chest discomfort
* breaking out in a cold sweat
* nausea or vomiting
* feeling lightheaded
* weakness in one part or on one side of your body
* slurred speech
Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein
thrombosis, DVT), and arteries (arterial thrombosis) have happened more often in
patients who are 50 years of age and older and with at least 1 heart disease
(cardiovascular) risk factor taking XELJANZ 5 mg twice daily or XELJANZ 10 mg
twice daily. Blood clots in the lungs have also happened in patients with
ulcerative colitis. Some people have died from these blood clots.
* Stop taking XELJANZ and tell your healthcare provider right away if you have
any signs and symptoms of blood clots such as sudden shortness of breath,
difficulty breathing, chest pain, swelling of a leg or arm, leg pain or
tenderness, or red or discolored skin in the leg or arm.
Tears (perforation) in the stomach or intestines. Tell your healthcare provider
if you have had diverticulitis (inflammation in parts of the large intestine) or
ulcers in your stomach or intestines. Some people taking XELJANZ can get tears
in their stomach or intestine. This happens most often in people who also take
nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate.
Tell your healthcare provider right away if you have fever, stomach-area pain
that does not go away, and a change in your bowel habits.
Serious allergic reactions can occur. Stop using XELJANZ and call your
healthcare provider right away if you have swelling of your lips, tongue,
throat, or get hives.
Changes in certain lab test results. Your doctor should do blood tests to check
your white and red blood cells before and while you are taking XELJANZ. Your
doctor should also check certain liver tests. You should not receive XELJANZ if
your lymphocyte count, neutrophil count, or red blood cell count is too low or
your liver function test levels are too high. Changes in lab test results may
cause your healthcare provider to stop your XELJANZ treatment for a time. Your
cholesterol levels should be checked 4 to 8 weeks after you start receiving
XELJANZ.
Before you use XELJANZ, tell your healthcare provider if you:
* Are being treated for an infection, have an infection that won’t go away or
keeps coming back, or think you have symptoms of an infection
* Have TB, or have been in close contact with someone with TB, or were born in,
lived in, or traveled where there is more risk for getting TB
* Have diabetes, chronic lung disease, HIV, or a weak immune system. People
with these conditions have a higher chance for infections
* Live or have lived in certain areas (such as Ohio and Mississippi River
Valleys and the Southwest) where there is an increased chance for getting
certain kinds of fungal infections
* Have or have had Hepatitis B or C
* Are a current or past smoker
* Have had any type of cancer
* Have had a heart attack, other heart problems or stroke
* Have had blood clots
* Have liver or kidney problems
* Have any stomach area (abdominal) pain or been diagnosed with diverticulitis
or ulcers in your stomach or intestines
* Have recently received or plan to receive a vaccine. People taking XELJANZ
should not receive live vaccines but can receive non-live vaccines
* Are pregnant, planning to become pregnant, breastfeeding, or planning to
breastfeed. You should not take XELJANZ and breastfeed
* Have had a reaction to tofacitinib or any of the ingredients
* Are taking other medicines, including prescription and over-the-counter
medicines, vitamins, and herbal supplements. Especially tell your healthcare
provider if you take any of the following medicines while taking XELJANZ
since this may increase your risk of infection:
* tocilizumab (Actemra®)
* etanercept (Enbrel®)
* adalimumab (Humira®)
* infliximab (Remicade®)
* rituximab (Rituxan®)
* abatacept (Orencia®)
* anakinra (Kineret®)
* certolizumab (Cimzia®)
* golimumab (Simponi®)
* ustekinumab (Stelara®)
* secukinumab (Cosentyx®)
* vedolizumab (Entyvio®)
* sarilumab (Kevzara®)
* azathioprine, cyclosporine, or other immunosuppressive drugs
* Tell your healthcare provider if you are taking medicines that affect the way
certain liver enzymes work. Ask your healthcare provider if you are not sure
if your medicine is one of these.
What are other possible side effects of XELJANZ/XELJANZ XR?
If you are a carrier of the Hepatitis B or C virus (viruses that affect the
liver), the virus may become active while you use XELJANZ. Your healthcare
provider may do blood tests before starting and while using treatment with
XELJANZ. Tell your healthcare provider if you have any signs of these symptoms:
feel very tired, little or no appetite, clay-colored bowel movements, chills,
muscle aches, skin rash, skin or eyes look yellow, vomiting, fevers, stomach
discomfort, or dark urine.
Common side effects in adults with rheumatoid arthritis and psoriatic arthritis
include upper respiratory tract infections (common cold, sinus infections),
headache, diarrhea, nasal congestion, sore throat, runny nose (nasopharyngitis),
and high blood pressure (hypertension).
Common side effects in adults with ulcerative colitis include nasal congestion,
sore throat, runny nose (nasopharyngitis), increased cholesterol levels,
headache, upper respiratory tract infections (common cold, sinus infections),
increased muscle enzyme levels, rash, diarrhea, and shingles (herpes zoster).
Common side effects in children (2 & older) with polyarticular course juvenile
arthritis include upper respiratory tract infections (common cold, sinus
infections), nasal congestion, sore throat, and runny nose (nasopharyngitis),
headache, fever, nausea, and vomiting.
XELJANZ & Pregnancy
XELJANZ may affect the ability of females to get pregnant. It is not known if
this will change after stopping XELJANZ. It is not known if XELJANZ will harm an
unborn baby.
* Pregnancy Registry: Pfizer has a registry for pregnant women who take
XELJANZ. The purpose of this registry is to check the health of the pregnant
mother and her baby. If you are pregnant or become pregnant while taking
XELJANZ, talk to your healthcare provider about how you can join this
pregnancy registry or you may contact the registry at 1-877-311-8972 to
enroll.
You and your healthcare provider should decide if you will take XELJANZ or
breastfeed. You should not do both. After you stop your treatment with XELJANZ
do not start breastfeeding again until 18 hours after your last dose of XELJANZ
or 36 hours after your last dose of XELJANZ XR.
What is XELJANZ/ XELJANZ XR/XELJANZ Oral Solution?
XELJANZ/XELJANZ XR (tofacitinib) is used to treat adults with:
* Moderately to severely active rheumatoid arthritis when 1 or more medicines
called tumor necrosis factor (TNF) blockers have been used, and did not work
well or cannot be tolerated
* Active psoriatic arthritis when 1 or more tumor necrosis factor (TNF) blocker
medicines have been used, and did not work well or cannot be tolerated
* Moderately to severely active ulcerative colitis when 1 or more tumor
necrosis factor (TNF) blocker medicines have been used, and did not work well
or cannot be tolerated
XELJANZ/XELJANZ Oral Solution is used to treat patients 2 years of age and older
with:
* Active polyarticular course juvenile arthritis when 1 or more tumor necrosis
factor (TNF) blocker medicines have been used, and did not work well or
cannot be tolerated
It is not known if XELJANZ/XELJANZ XR is safe and effective in people with
Hepatitis B or C.
XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended for people with
severe liver problems.
It is not known if XELJANZ/XELJANZ Oral Solution is safe and effective in
children for treatment other than active polyarticular course juvenile
arthritis.
It is not known if XELJANZ XR is safe and effective in children.
Please see full Prescribing Information, including BOXED WARNING and Medication
Guide.
* Indications
* Important Safety Information
* Prescribing Information
* Medication Guide
* For Healthcare Professionals
Indications
Important Safety Information
* Select Condition
* Moderate to Severe Rheumatoid Arthritis
* ActivePsoriatic Arthritis
* Moderate to Severe Ulcerative Colitis
* Active Polyarticular Course Juvenile Idiopathic
Arthritis
* Doctor Discussion Guide
* Safety / Side Effects
* Savings & Support
* Sign Up
Sign Up
SIGN UP FOR XELJANZ SUPPORT
Whether you’ve just started treatment or are considering XELJANZ, you can get
information, lifestyle tips, and tools for different steps of your treatment
plan.
To get started, select the condition you’d like to receive information and
support tools for:
Moderate to Severe Rheumatoid Arthritis
Active Psoriatic Arthritis
Moderate to Severe Ulcerative Colitis
WE'RE SORRY.
A temporary technical issue prevents us from bringing you the information you
requested. Please try again later. Need additional assistance? Please
contact us.
All fields are required unless marked optional.
First Name
Last Name
Email
Have you already been prescribed XELJANZ?
Yes
No
* Step 1
* Step 2
* Done
Please complete the above selections for treatment indication, name, email, and
current prescription status to complete sign-up form.
All fields are required unless marked optional.
Approximately when did you start treatment with XELJANZ?
Approximately when is your next doctor’s appointment?
Approximately when is your next doctor’s appointment?
Have you already tried certain medicines, and are you interested in discussing
available prescription treatment options with your doctor?
I have not started yet/I don’t know
Approximately when is your next doctor’s appointment?
I don’t know
I have not started yet/I don’t know
Approximately when is your next doctor’s appointment?
I don’t know
I have not started yet/I don’t know
I don’t know
I don’t know
Yes
No
How are you currently treating your rheumatoid arthritis? - Optional
How are you currently treating your active psoriatic arthritis? - Optional
How are you currently treating your ulcerative colitis? – Optional
Pill
Injection
Infusion
I don’t know
The XELJANZ+YOU Support Program provides tools and information to help you take
an active role in your treatment with XELJANZ and better manage your disease.
You’ll also receive resources in the mail.
The XELJANZ+YOU Support Program provides tools and information to help you take
an active role in your treatment with XELJANZ and better manage your disease.
You’ll also receive a welcome kit in the mail.
By completing this registration, you’ll also receive resources in the mail to
help you understand how RA may be impacting you. Materials include a welcome kit
that features an informational brochure, spiral-bound RA journal, and loop cloth
assistance tool.
By completing this registration, you’ll also receive resources in the mail to
help you understand how psoriatic arthritis may be impacting you. Materials
include a welcome kit that features a psoriatic arthritis-friendly tote bag, a
psoriatic arthritis journal, a day-to-day symptom tracker, and a doctor
discussion guide.
Continue this short registration to receive a welcome kit in the mail. This kit
contains additional resources and information about XELJANZ and UC, so you can
prepare for a productive conversation with your doctor. – Optional
Street Address 1
Street Address 2 - Optional
City
State
Select Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware
District of Columbia Florida Georgia Guam Hawaii Idaho Illinois Indiana Iowa
Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota
Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico
New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Puerto
Rico Rhode Island South Carolina South Dakota Tennessee Texas US Virgin Islands
Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming
ZIP Code
PLEASE VERIFY THE FOLLOWING INFORMATION TO RECEIVE A CO-PAY SAVINGS CARD.
* I do not have insurance from any federal healthcare program (including
Medicare, Medicaid, TRICARE, or any other state or federal medical
pharmaceutical benefit program or pharmaceutical assistance program).
* I am not over 65 years of age and retired, and if applicable, neither is my
partner.
* I do not receive Social Security Disability or any other Social Security
Administration benefit.
* I am not active duty military, and if applicable, neither is an immediate
family member.
* I agree with the limits, terms, and conditions that apply.
I meet the defined requirements.
By checking this box, I verify that I am age 18 or older.
I agree to receive communications via email, social media channels, and
materials in the mail from Pfizer or parties acting on its behalf containing
helpful tools and information on XELJANZ and living with rheumatoid arthritis.
I agree to receive communications via email, social media channels, and
materials in the mail from Pfizer or parties acting on its behalf containing
helpful tools and information on XELJANZ and living with psoriatic arthritis.
I agree to receive communications via email, social media channels, and
materials in the mail from Pfizer or parties acting on its behalf containing
helpful tools and information on XELJANZ and living with ulcerative colitis.
XELSOURCE & XELJANZ ACCESS TERMS & CONDITIONS
PFIZER PATIENT ASSISTANCE PROGRAM ELIGIBILITY CRITERIA
* The Pfizer Patient Assistance Program is not health insurance and is
available for eligible uninsured/underinsured patients only.
* Offer is only available to patients who meet financial and other criteria.
* This offer does not require, nor will it be made contingent on, purchase
requirements of any kind.
* No claim for reimbursement or credit for any costs associated with the
medicine(s) may be submitted to any prescription insurance provider or payer,
including Medicare Part D plans.
* Pfizer reserves the right to amend, rescind, or discontinue this program at
any time without notification.
* Offer good only in the US and Puerto Rico.
* Patient must be a resident of the US or Puerto Rico.
* Prescription must be provided by a healthcare provider licensed in the US or
Puerto Rico.
* Patient must be treated in the outpatient setting of care.
* Additional eligibility criteria may apply. Contact XELSOURCE for details.
INTERIM CARE RX PROGRAM TERMS & CONDITIONS
* Interim Care Rx is not health insurance and is available for eligible,
commercially insured patients only.
* Offer is only available to patients who have been diagnosed with an
FDA-approved indication for XELJANZ/XELJANZ XR.
* No claim for reimbursement for product dispensed pursuant to this offer may
be submitted to any third-party payer.
* Not available to patients covered under government plans such as Medicaid,
Medicare or other federal or state healthcare programs, including any state
prescription drug assistance programs and the Government Health Insurance
Plan or for residents of Massachusetts, Michigan, Minnesota, Missouri, Ohio,
or Rhode Island.
* Available in 30-day supply. Refills are subject to limitations.
* Interim Care Rx offer does not require, nor will be made contingent on,
purchase requirements of any kind.
* Pfizer reserves the right to amend, rescind, or discontinue this program at
any time without notification.
* Interim Care Rx can only be dispensed by the exclusive pharmacy and only
after benefits investigation has been completed and a delay occurs in the
prior authorization or appeals process.
* Offer good only in the US and Puerto Rico.
* Prescription must be provided by a healthcare provider licensed in the US or
Puerto Rico.
* Additional eligibility criteria may apply. Contact XELSOURCE for details.
VOUCHER TERMS AND CONDITIONS
By redeeming this voucher, you acknowledge that you currently meet the
eligibility criteria and will comply with the terms & conditions described
below:
* You will receive a one-time, 30-day supply of XELJANZ.
* Only new patients may use this voucher. By redeeming this voucher, you
certify that you are not currently using XELJANZ.
* An original voucher and a valid prescription must be presented to the
pharmacy.
* The voucher will be accepted only at participating pharmacies.*
* You must not submit any claim for reimbursement for product dispensed
pursuant to this voucher to any third-party payor, including Medicare,
Medicaid, or any other federal or state health care program. You cannot apply
the value of the free product received through this voucher toward any
government insurance benefit out-of-pocket spending calculations, such as
Medicare Part D True Out-of-Pocket Costs (TrOOP).
* You must be 18 years of age or older to redeem this voucher.
* This voucher is not valid where prohibited by law.
* This voucher cannot be combined with any other savings, free trial or similar
offer for the specified prescription. This voucher should not be combined
with samples for the specified prescription.
* This free trial voucher is not health insurance. This free trial voucher is
not intended to address delays or gaps in health insurance coverage for the
specified prescription.
* Offer good only in the US and Puerto Rico.
* No purchase is necessary.
* Patients have no obligation to continue to use XELJANZ.
* Pfizer reserves the right to rescind, revoke, or amend this offer without
notice.
* This voucher expires 12/31/2021.
*MA residents may select their pharmacy. Otherwise, this free trial will be
supplied through XELSOURCE.
CO-PAY CARD TERMS AND CONDITIONS
By using the XELJANZ/XELJANZ XR Co-pay Savings Card (the “Card”), you
acknowledge that you currently meet the eligibility criteria and will comply
with the following terms and conditions.
* Patients are not eligible to use this card if they are enrolled in a state or
federally funded insurance program, including but not limited to Medicare,
Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug
assistance program, or the Government Health Insurance Plan available in
Puerto Rico (formerly known as “La Reforma de Salud”).
* Patient must have private insurance. Offer is not valid for cash paying
patients.
* You will receive a maximum benefit of $6,000–$15,000 per calendar year, which
is defined by the date of enrollment through December 31st of the enrollment
year. After a maximum is reached, you will be responsible for paying the
remaining monthly out-of-pocket costs.
* This Card is not valid when the entire cost of your prescription drug is
eligible to be reimbursed by your private insurance plan or other private
health or pharmacy benefit programs.
* You must deduct the value of this card from any reimbursement request
submitted to your private insurance plan, either directly by you or on your
behalf.
* You are responsible for reporting use of the Card to any private insurer,
health plan, or other third party who pays for or reimburses any part of the
prescription filled using the Card, as may be required. You should not use
the Card if your insurer or health plan prohibits use of manufacturer Cards.
* You must be 18 years of age or older to redeem the Card.
* The Card is not valid where prohibited by law.
* The Card cannot be combined with any other savings, free trial, or similar
offer for the specified prescription.
* The Card will be accepted only at participating pharmacies.
* If your pharmacy does not participate, you may be able to submit a request
for a rebate in connection with this offer.
* The Card is not health insurance.
* Offer good only in the US and Puerto Rico.
* The Card is limited to 1 per person during this offering period and is not
transferable.
* The Card may be used once per month for the life of the program.
* No other purchase is necessary.
* Data related to your redemption of the Card may be collected, analyzed, and
shared with Pfizer, for market research and other purposes related to
assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and
de-identified; it will be combined with data related to other Card
redemptions and will not identify you.
* Pfizer reserves the right to rescind, revoke, or amend the program without
notice.
* Card and Program expires 12/31/2021.
XSAVINGS MOBILE TEXT PROGRAM TERMS & CONDITIONS
User texts "XPROGRAM" to short code 50336.
Text HELP for help, STOP to opt out.
Patients may receive up to 10 messages per month.
Message and data rates may apply.
1. By opting into the XSAVINGS mobile texting program (Program), you consent
to receive up to 10 text messages and/or push notifications from Pfizer
Inc. Such messages may be marketing or non-marketing messages and may
include co-pay related information, fill confirmation, website information,
etc. Messages may be delayed or undelivered for various factors. TrialCard,
carriers (including, but not limited to, T-Mobile) and any service
providers utilized by TrialCard to send messages are not liable for delayed
or undelivered messages.
2. To stop receiving text messages, text STOP to 50336. DOING SO WILL ONLY OPT
YOU OUT OF THIS PROGRAM; you will remain opted in to any other Pfizer Inc.
text message program(s) into which you opted separately.
3. To request more information or to obtain help, text HELP to 50336. You can
also call customer service at 1-844-935-5269.
4. You represent that you are the account holder for the mobile telephone
number(s) that you provide to opt into the Program. You are responsible for
notifying Pfizer Inc. immediately if you change your mobile telephone
number. You may notify Pfizer Inc. of a number change by calling
1-844-935-5269.
5. Message and data rates may apply to each text message sent or received in
connection with the texting program, as provided in your mobile telephone
service rate plan (please contact your mobile telephone carrier for pricing
plans). Applicable roaming charges may apply. Charges are both billed and
payable to your mobile service provider or deducted from your prepaid
account. Pfizer Inc. does not impose a separate fee for sending text
messages.
6. Data obtained from you in connection with this Program may include your
telephone number, your carrier's name, and details of the message (date,
time, and content). Pfizer Inc. may use this information to contact you and
to provide the services you request.
7. For information on data collection and use, please read our full corporate
Privacy Policy, which is incorporated by reference into these Terms.
8. Pfizer Inc. will not be liable for any delays in the receipt of any SMS
messages, as delivery is subject to effective transmission from your
network operator.
9. This Program is available only on these US participating mobile carriers:
Verizon Wireless, Sprint, Boost Mobile, T-Mobile, AT&T, Atlantic
Tele-Network International (ATNI), Alaska Communications Systems (ACS),
ASTAC, Bandwidth.com (includes Republic Wireless), Blue Wireless, Bluegrass
Cellular, Breakaway Wireless, Brightlink, C Spire Wireless (aka Cellular
South), Carolina West Wireless, CellCom, Cellone Nation, Cellular One of
N.E. Arizona, Chariton Valley Cellular, Chat Mobility, Copper Valley
Telecom, Cordova Wireless, Cross Wireless, CTC, Custer Telephone, East
Kentucky Network (Appalachian Wireless), Enflick, GCI Communications,
Google Voice, Illinois Valley Cellular, Inland Cellular, Inteliquent,
iWireless, Leaco Rural Telephone Cooperative, Limitless Mobile, Mid-Rivers
Communications, MobileNation/SI Wireless, MTA Wireless/Matanuska Kenai,
Nemont CDMA, Nemont US UMTS, NewCore Wireless, Nex-Tech Wireless, NNTC
Wireless, Northwest Missouri Cellular, Pine Belt Wireless, Pine Cellular,
Pioneer Cellular, PTCI, Shelcomm, Silver Star PCS, Snake River PCS,
SouthernLINC, SouthernLINC LTE, SRT, STRATA Networks, Standing Rock (SRTI),
Thumb Cellular, Triangle Wireless, Union Wireless, US Cellular, United
Wireless, Viaero Wireless, Virgin Mobile, West Central Wireless.
10. You agree to indemnify Pfizer Inc. and any third parties texting on its
behalf in full for all claims, expenses, and damages related to or caused,
in whole or in part, by your failure to immediately notify us if you change
your telephone number, including but not limited to all claims, expenses,
and damages related to or arising under the Telephone Consumer Protection
Act.
11. Pfizer Inc. may immediately suspend or terminate your participation in the
Program if it believes you are in breach of these SMS Terms and Conditions.
Your participation in this Program is also subject to termination in the
event that your mobile telephone service terminates or lapses. Pfizer Inc.
reserves the right to modify or discontinue, temporarily or permanently,
all or any part of the Program, with or without notice.
12. Pfizer Inc. may revise, modify, or amend these SMS Terms and Conditions at
any time. Any such revision, modification, or amendment shall take effect
when it is posted to Pfizer Inc.'s website. You agree to review these SMS
Terms and Conditions periodically to ensure that you are aware of any
changes. Your continued consent to receive text messages will indicate your
acceptance of those changes.
If you have questions or are in need of additional support, call 1-844-935-5269
or visit www.XELJANZ.com
* Privacy Policy|
* Terms of Use|
* Unsubscribe|
* Contact Us
Please see full Prescribing Information, including BOXED WARNING and Medication
Guide.
You are encouraged to report adverse events related to Pfizer products by
calling 1-800-438-1985 (U.S. only). If you prefer, you may contact the U.S. Food
and Drug Administration (FDA) directly. Visit http://fda.gov/MedWatch or call
1-800-FDA-1088.
If your doctor has prescribed XELJANZ and you need help paying for it, XELSOURCE
may be able to assist, depending on eligibility, terms and conditions.
Call 1-844-935-5269 Monday through Friday, 8:00 AM–8:00 PM ET, for more
information.
This site is intended only for U.S. residents. The products discussed in this
site may have different product labeling in different countries. The information
provided is for educational purposes only and is not intended to replace
discussions with a healthcare provider.
XELJANZ is a registered trademark of Pfizer Inc. The brand names included
throughout are the properties of their respective owners.
XELJANZ (tofacitinib) is available in 5 mg and 10 mg tablets.
XELJANZ XR (tofacitinib) is available in 11 mg and 22 mg extended-release
tablets.
XELJANZ Oral Solution (tofacitinib) is available in 1 mg/mL oral solution.
AdChoices
© 2022 Pfizer Inc. All rights reserved.
PP-XEL-USA-7621
© 2022 Pfizer Inc. All rights reserved.
AdChoices
PP-XEL-USA-7621
Indications
XELJANZ/XELJANZ XR (tofacitinib) is used to treat adults who have tried TNF
blockers with:
* Moderately to severely active rheumatoid arthritis when 1 or more medicines
called tumor necrosis factor (TNF) blockers have been used, and did not work
well or cannot be tolerated
* Active psoriatic arthritis when 1 or more tumor necrosis factor (TNF) blocker
medicines have been used, and did not work well or cannot be tolerated
* Moderately to severely active ulcerative colitis when 1 or more tumor
necrosis factor (TNF) blocker medicines have been used, and did not work well
or cannot be tolerated
XELJANZ/XELJANZ Oral Solution is used to treat patients 2 years of age and older
with:
* Active polyarticular course juvenile arthritis when 1 or more tumor necrosis
factor (TNF) blocker medicines have been used, and did not work well or
cannot be tolerated
It is not known if XELJANZ/XELJANZ XR is safe and effective in people with
Hepatitis B or C.
XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended for people with
severe liver problems.
It is not known if XELJANZ/XELJANZ Oral Solution is safe and effective in
children for treatment other than active polyarticular course juvenile
arthritis.
It is not known if XELJANZ XR is safe and effective in children.
XELJANZ/XELJANZ XR (tofacitinib) is used to treat adults who have tried TNF
blockers with:
* Moderately to severely active rheumatoid » Read More
Important Safety Information
The safety information below applies to all marketed formulations of XELJANZ.
Specific risks associated with certain dosing are noted.
Serious infections. XELJANZ can lower the ability of your immune system to fight
infections. Do not start taking XELJANZ if you have any kind of infection unless
your healthcare provider tells you it is okay. Serious infections have happened
in people taking XELJANZ. These serious infections include tuberculosis (TB) and
infections caused by bacteria, fungi, or viruses that can spread throughout the
body. Some people have died from these infections. Your healthcare provider
should test you for TB before starting and during treatment with XELJANZ. You
should not start taking XELJANZ if you have any kind of infection unless your
healthcare professional tells you it is okay.
Before and after starting XELJANZ, tell your doctor if you have an infection or
symptoms of an infection, including:
* fever, sweating, or chills
* cough
* blood in phlegm
* warm, red, or painful skin or sores on your body
* burning when you urinate
* urinating more often than normal
* muscle aches
* shortness of breath
* weight loss
* diarrhea or stomach pain
* feeling very tired
Increased risk of death in people 50 years of age and older who have at least 1
heart disease (cardiovascular) risk factor and are taking XELJANZ 5 mg twice
daily or XELJANZ 10 mg twice daily.
Cancer. XELJANZ may increase your risk of certain cancers by changing the way
your immune system works. Lymphoma and other cancers, including skin cancers,
can happen. People taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily
have a higher risk of certain cancers including lymphoma and lung cancer,
especially if you are a current or past smoker. Tell your healthcare provider if
you have ever had any type of cancer.
Higher dose. People with ulcerative colitis taking the higher dose of XELJANZ
(10 mg twice daily) or XELJANZ XR (22 mg one time each day) have a higher risk
of serious infections, shingles, or skin cancers.
Immune system problem. Some people who have taken XELJANZ with certain other
medicines to prevent kidney transplant rejection have had a problem with certain
white blood cells growing out of control (Epstein Barr Virus–associated
post-transplant lymphoproliferative disorder).
Increased risk of major cardiovascular events such as heart attack, stroke or
death in people 50 years of age and older who have at least 1 heart disease
(cardiovascular) risk factor and are taking XELJANZ 5 mg twice daily or
XELJANZ 10 mg twice daily, especially if you are a current or past smoker.
Get emergency help right away if you have any symptoms of a heart attack or
stroke while taking XELJANZ, including:
* discomfort in the center of your chest that lasts for more than a few
minutes, or that goes away and comes back
* severe tightness, pain, pressure, or heaviness in your chest, throat, neck,
or jaw
* pain or discomfort in your arms, back, neck, jaw, or stomach
* shortness of breath with or without chest discomfort
* breaking out in a cold sweat
* nausea or vomiting
* feeling lightheaded
* weakness in one part or on one side of your body
* slurred speech
Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein
thrombosis, DVT), and arteries (arterial thrombosis) have happened more often in
patients who are 50 years of age and older and with at least 1 heart disease
(cardiovascular) risk factor taking XELJANZ 5 mg twice daily or XELJANZ 10 mg
twice daily. Blood clots in the lungs have also happened in patients with
ulcerative colitis. Some people have died from these blood clots.
* Stop taking XELJANZ and tell your healthcare provider right away if you have
any signs and symptoms of blood clots such as sudden shortness of breath,
difficulty breathing, chest pain, swelling of a leg or arm, leg pain or
tenderness, or red or discolored skin in the leg or arm.
Tears (perforation) in the stomach or intestines. Tell your healthcare provider
if you have had diverticulitis (inflammation in parts of the large intestine) or
ulcers in your stomach or intestines. Some people taking XELJANZ can get tears
in their stomach or intestine. This happens most often in people who also take
nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate.
Tell your healthcare provider right away if you have fever, stomach-area pain
that does not go away, and a change in your bowel habits.
Serious allergic reactions can occur. Stop using XELJANZ and call your
healthcare provider right away if you have swelling of your lips, tongue,
throat, or get hives.
Changes in certain lab test results. Your doctor should do blood tests to check
your white and red blood cells before and while you are taking XELJANZ. Your
doctor should also check certain liver tests. You should not receive XELJANZ if
your lymphocyte count, neutrophil count, or red blood cell count is too low or
your liver function test levels are too high. Changes in lab test results may
cause your healthcare provider to stop your XELJANZ treatment for a time. Your
cholesterol levels should be checked 4 to 8 weeks after you start receiving
XELJANZ.
Before you use XELJANZ, tell your healthcare provider if you:
* Are being treated for an infection, have an infection that won’t go away or
keeps coming back, or think you have symptoms of an infection
* Have TB, or have been in close contact with someone with TB, or were born in,
lived in, or traveled where there is more risk for getting TB
* Have diabetes, chronic lung disease, HIV, or a weak immune system. People
with these conditions have a higher chance for infections
* Live or have lived in certain areas (such as Ohio and Mississippi River
Valleys and the Southwest) where there is an increased chance for getting
certain kinds of fungal infections
* Have or have had Hepatitis B or C
* Are a current or past smoker
* Have had any type of cancer
* Have had a heart attack, other heart problems or stroke
* Have had blood clots
* Have liver or kidney problems
* Have any stomach area (abdominal) pain or been diagnosed with diverticulitis
or ulcers in your stomach or intestines
* Have recently received or plan to receive a vaccine. People taking XELJANZ
should not receive live vaccines but can receive non-live vaccines
* Are pregnant, planning to become pregnant, breastfeeding, or planning to
breastfeed. You should not take XELJANZ and breastfeed
* Have had a reaction to tofacitinib or any of the ingredients
* Are taking other medicines, including prescription and over-the-counter
medicines, vitamins, and herbal supplements. Especially tell your healthcare
provider if you take any of the following medicines while taking XELJANZ
since this may increase your risk of infection:
* tocilizumab (Actemra®)
* etanercept (Enbrel®)
* adalimumab (Humira®)
* infliximab (Remicade®)
* rituximab (Rituxan®)
* abatacept (Orencia®)
* anakinra (Kineret®)
* certolizumab (Cimzia®)
* golimumab (Simponi®)
* ustekinumab (Stelara®)
* secukinumab (Cosentyx®)
* vedolizumab (Entyvio®)
* sarilumab (Kevzara®)
* azathioprine, cyclosporine, or other immunosuppressive drugs
* Tell your healthcare provider if you are taking medicines that affect the way
certain liver enzymes work. Ask your healthcare provider if you are not sure
if your medicine is one of these.
What are other possible side effects of XELJANZ/XELJANZ XR?
If you are a carrier of the Hepatitis B or C virus (viruses that affect the
liver), the virus may become active while you use XELJANZ. Your healthcare
provider may do blood tests before starting and while using treatment with
XELJANZ. Tell your healthcare provider if you have any signs of these symptoms:
feel very tired, little or no appetite, clay-colored bowel movements, chills,
muscle aches, skin rash, skin or eyes look yellow, vomiting, fevers, stomach
discomfort, or dark urine.
Common side effects in adults with rheumatoid arthritis and psoriatic arthritis
include upper respiratory tract infections (common cold, sinus infections),
headache, diarrhea, nasal congestion, sore throat, runny nose (nasopharyngitis),
and high blood pressure (hypertension).
Common side effects in adults with ulcerative colitis include nasal congestion,
sore throat, runny nose (nasopharyngitis), increased cholesterol levels,
headache, upper respiratory tract infections (common cold, sinus infections),
increased muscle enzyme levels, rash, diarrhea, and shingles (herpes zoster).
Common side effects in children (2 & older) with polyarticular course juvenile
arthritis include upper respiratory tract infections (common cold, sinus
infections), nasal congestion, sore throat, and runny nose (nasopharyngitis),
headache, fever, nausea, and vomiting.
XELJANZ & Pregnancy
XELJANZ may affect the ability of females to get pregnant. It is not known if
this will change after stopping XELJANZ. It is not known if XELJANZ will harm an
unborn baby.
* Pregnancy Registry: Pfizer has a registry for pregnant women who take
XELJANZ. The purpose of this registry is to check the health of the pregnant
mother and her baby. If you are pregnant or become pregnant while taking
XELJANZ, talk to your healthcare provider about how you can join this
pregnancy registry or you may contact the registry at 1-877-311-8972 to
enroll.
You and your healthcare provider should decide if you will take XELJANZ or
breastfeed. You should not do both. After you stop your treatment with XELJANZ
do not start breastfeeding again until 18 hours after your last dose of XELJANZ
or 36 hours after your last dose of XELJANZ XR.
Please see full Prescribing Information, including BOXED WARNING and Medication
Guide.
Indications
XELJANZ/XELJANZ XR (tofacitinib) is used to treat adults who have tried TNF
blockers with:
* Moderately to severely active rheumatoid arthritis when 1 or more medicines
called tumor necrosis factor (TNF) blockers have been used, and did not work
well or cannot be tolerated
* Active psoriatic arthritis when 1 or more tumor necrosis factor (TNF) blocker
medicines have been used, and did not work well or cannot be tolerated
* Moderately to severely active ulcerative colitis when 1 or more tumor
necrosis factor (TNF) blocker medicines have been used, and did not work well
or cannot be tolerated
XELJANZ/XELJANZ Oral Solution is used to treat patients 2 years of age and older
with:
* Active polyarticular course juvenile arthritis when 1 or more tumor necrosis
factor (TNF) blocker medicines have been used, and did not work well or
cannot be tolerated
It is not known if XELJANZ/XELJANZ XR is safe and effective in people with
Hepatitis B or C.
XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended for people with
severe liver problems.
It is not known if XELJANZ/XELJANZ Oral Solution is safe and effective in
children for treatment other than active polyarticular course juvenile
arthritis.
It is not known if XELJANZ XR is safe and effective in children.
XELJANZ/XELJANZ XR (tofacitinib) is used to treat adults who have tried TNF
blockers with:
* Moderately to severely active rheumatoid arthritis when 1 or more medicines
called tumor necrosis factor (TNF) blockers have...Read More
XELJANZ/XELJANZ XR (tofacitinib) is used to treat adults who have tried TNF
blockers with:
* Moderately to severely active rheumatoid » Read More
Important Safety Information
The safety information below applies to all marketed formulations of XELJANZ.
Specific risks associated with certain dosing are noted.
Serious infections. XELJANZ can lower the ability of your immune system to fight
infections. Do not start taking XELJANZ if you have any kind of infection unless
your healthcare provider tells you it is okay. Serious infections have happened
in people taking XELJANZ. These serious infections include tuberculosis (TB) and
infections caused by bacteria, fungi, or viruses that can spread throughout the
body. Some people have died from these infections. Your healthcare provider
should test you for TB before starting and during treatment with XELJANZ. You
should not start taking XELJANZ if you have any kind of infection unless your
healthcare professional tells you it is okay.
Before and after starting XELJANZ, tell your doctor if you have an infection or
symptoms of an infection, including:
* fever, sweating, or chills
* cough
* blood in phlegm
* warm, red, or painful skin or sores on your body
* burning when you urinate
* urinating more often than normal
* muscle aches
* shortness of breath
* weight loss
* diarrhea or stomach pain
* feeling very tired
Increased risk of death in people 50 years of age and older who have at least 1
heart disease (cardiovascular) risk factor and are taking XELJANZ 5 mg twice
daily or XELJANZ 10 mg twice daily.
Cancer. XELJANZ may increase your risk of certain cancers by changing the way
your immune system works. Lymphoma and other cancers, including skin cancers,
can happen. People taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily
have a higher risk of certain cancers including lymphoma and lung cancer,
especially if you are a current or past smoker. Tell your healthcare provider if
you have ever had any type of cancer.
Higher dose. People with ulcerative colitis taking the higher dose of XELJANZ
(10 mg twice daily) or XELJANZ XR (22 mg one time each day) have a higher risk
of serious infections, shingles, or skin cancers.
Immune system problem. Some people who have taken XELJANZ with certain other
medicines to prevent kidney transplant rejection have had a problem with certain
white blood cells growing out of control (Epstein Barr Virus–associated
post-transplant lymphoproliferative disorder).
Increased risk of major cardiovascular events such as heart attack, stroke or
death in people 50 years of age and older who have at least 1 heart disease
(cardiovascular) risk factor and are taking XELJANZ 5 mg twice daily or
XELJANZ 10 mg twice daily, especially if you are a current or past smoker.
Get emergency help right away if you have any symptoms of a heart attack or
stroke while taking XELJANZ, including:
* discomfort in the center of your chest that lasts for more than a few
minutes, or that goes away and comes back
* severe tightness, pain, pressure, or heaviness in your chest, throat, neck,
or jaw
* pain or discomfort in your arms, back, neck, jaw, or stomach
* shortness of breath with or without chest discomfort
* breaking out in a cold sweat
* nausea or vomiting
* feeling lightheaded
* weakness in one part or on one side of your body
* slurred speech
Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein
thrombosis, DVT), and arteries (arterial thrombosis) have happened more often in
patients who are 50 years of age and older and with at least 1 heart disease
(cardiovascular) risk factor taking XELJANZ 5 mg twice daily or XELJANZ 10 mg
twice daily. Blood clots in the lungs have also happened in patients with
ulcerative colitis. Some people have died from these blood clots.
* Stop taking XELJANZ and tell your healthcare provider right away if you have
any signs and symptoms of blood clots such as sudden shortness of breath,
difficulty breathing, chest pain, swelling of a leg or arm, leg pain or
tenderness, or red or discolored skin in the leg or arm.
Tears (perforation) in the stomach or intestines. Tell your healthcare provider
if you have had diverticulitis (inflammation in parts of the large intestine) or
ulcers in your stomach or intestines. Some people taking XELJANZ can get tears
in their stomach or intestine. This happens most often in people who also take
nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate.
Tell your healthcare provider right away if you have fever, stomach-area pain
that does not go away, and a change in your bowel habits.
Serious allergic reactions can occur. Stop using XELJANZ and call your
healthcare provider right away if you have swelling of your lips, tongue,
throat, or get hives.
Changes in certain lab test results. Your doctor should do blood tests to check
your white and red blood cells before and while you are taking XELJANZ. Your
doctor should also check certain liver tests. You should not receive XELJANZ if
your lymphocyte count, neutrophil count, or red blood cell count is too low or
your liver function test levels are too high. Changes in lab test results may
cause your healthcare provider to stop your XELJANZ treatment for a time. Your
cholesterol levels should be checked 4 to 8 weeks after you start receiving
XELJANZ.
Before you use XELJANZ, tell your healthcare provider if you:
* Are being treated for an infection, have an infection that won’t go away or
keeps coming back, or think you have symptoms of an infection
* Have TB, or have been in close contact with someone with TB, or were born in,
lived in, or traveled where there is more risk for getting TB
* Have diabetes, chronic lung disease, HIV, or a weak immune system. People
with these conditions have a higher chance for infections
* Live or have lived in certain areas (such as Ohio and Mississippi River
Valleys and the Southwest) where there is an increased chance for getting
certain kinds of fungal infections
* Have or have had Hepatitis B or C
* Are a current or past smoker
* Have had any type of cancer
* Have had a heart attack, other heart problems or stroke
* Have had blood clots
* Have liver or kidney problems
* Have any stomach area (abdominal) pain or been diagnosed with diverticulitis
or ulcers in your stomach or intestines
* Have recently received or plan to receive a vaccine. People taking XELJANZ
should not receive live vaccines but can receive non-live vaccines
* Are pregnant, planning to become pregnant, breastfeeding, or planning to
breastfeed. You should not take XELJANZ and breastfeed
* Have had a reaction to tofacitinib or any of the ingredients
* Are taking other medicines, including prescription and over-the-counter
medicines, vitamins, and herbal supplements. Especially tell your healthcare
provider if you take any of the following medicines while taking XELJANZ
since this may increase your risk of infection:
* tocilizumab (Actemra®)
* etanercept (Enbrel®)
* adalimumab (Humira®)
* infliximab (Remicade®)
* rituximab (Rituxan®)
* abatacept (Orencia®)
* anakinra (Kineret®)
* certolizumab (Cimzia®)
* golimumab (Simponi®)
* ustekinumab (Stelara®)
* secukinumab (Cosentyx®)
* vedolizumab (Entyvio®)
* sarilumab (Kevzara®)
* azathioprine, cyclosporine, or other immunosuppressive drugs
* Tell your healthcare provider if you are taking medicines that affect the way
certain liver enzymes work. Ask your healthcare provider if you are not sure
if your medicine is one of these.
What are other possible side effects of XELJANZ/XELJANZ XR?
If you are a carrier of the Hepatitis B or C virus (viruses that affect the
liver), the virus may become active while you use XELJANZ. Your healthcare
provider may do blood tests before starting and while using treatment with
XELJANZ. Tell your healthcare provider if you have any signs of these symptoms:
feel very tired, little or no appetite, clay-colored bowel movements, chills,
muscle aches, skin rash, skin or eyes look yellow, vomiting, fevers, stomach
discomfort, or dark urine.
Common side effects in adults with rheumatoid arthritis and psoriatic arthritis
include upper respiratory tract infections (common cold, sinus infections),
headache, diarrhea, nasal congestion, sore throat, runny nose (nasopharyngitis),
and high blood pressure (hypertension).
Common side effects in adults with ulcerative colitis include nasal congestion,
sore throat, runny nose (nasopharyngitis), increased cholesterol levels,
headache, upper respiratory tract infections (common cold, sinus infections),
increased muscle enzyme levels, rash, diarrhea, and shingles (herpes zoster).
Common side effects in children (2 & older) with polyarticular course juvenile
arthritis include upper respiratory tract infections (common cold, sinus
infections), nasal congestion, sore throat, and runny nose (nasopharyngitis),
headache, fever, nausea, and vomiting.
XELJANZ & Pregnancy
XELJANZ may affect the ability of females to get pregnant. It is not known if
this will change after stopping XELJANZ. It is not known if XELJANZ will harm an
unborn baby.
* Pregnancy Registry: Pfizer has a registry for pregnant women who take
XELJANZ. The purpose of this registry is to check the health of the pregnant
mother and her baby. If you are pregnant or become pregnant while taking
XELJANZ, talk to your healthcare provider about how you can join this
pregnancy registry or you may contact the registry at 1-877-311-8972 to
enroll.
You and your healthcare provider should decide if you will take XELJANZ or
breastfeed. You should not do both. After you stop your treatment with XELJANZ
do not start breastfeeding again until 18 hours after your last dose of XELJANZ
or 36 hours after your last dose of XELJANZ XR.
Please see full Prescribing Information, including BOXED WARNING and Medication
Guide.
CONTACT US
×
If you have questions, concerns, or comments, please call our XELJANZ
Information Center toll-free at 1-844-935-5269 Monday through Friday, 8:00
AM–8:00 PM ET.
Patients should always ask their doctors for medical advice about adverse
events. You are encouraged to report adverse events or product quality
complaints related to Pfizer products by calling 1-800-438-1985 (U.S. only). If
you prefer, you may contact the U.S. Food and Drug Administration (FDA)
directly. Visit http://www.fda.gov/MedWatch or call 1-800-FDA-1088. By clicking
on this link, you will be leaving XELJANZ.com. This website is neither owned nor
controlled by Pfizer. Pfizer does not endorse and is not responsible for the
content and services of this site.
YOU ARE NOW LEAVING THIS PFIZER SITE
Links to other sites are provided as a convenience to the visitor. Pfizer
accepts no responsibility for the content of linked sites.
Would you like to continue?
YES
NO
YOU ARE NOW LEAVING XELJANZ.COM
The information provided on xeljanzpro.com is intended only for healthcare
professionals in the United States.
Would you like to continue?
YES
NO
YOU ARE NOW LEAVING THIS PFIZER SITE
Links to other sites are provided as a convenience to the visitor. Pfizer
accepts no responsibility for the content of linked sites.
Would you like to continue?
YES
NO
XELSOURCE & XELJANZ ACCESS TERMS & CONDITIONS
PFIZER PATIENT ASSISTANCE PROGRAM ELIGIBILITY CRITERIA
* The Pfizer Patient Assistance Program is not health insurance and is
available for eligible uninsured/underinsured patients only.
* Offer is only available to patients who meet financial and other criteria.
* This offer does not require, nor will it be made contingent on, purchase
requirements of any kind.
* No claim for reimbursement or credit for any costs associated with the
medicine(s) may be submitted to any prescription insurance provider or payer,
including Medicare Part D plans.
* Pfizer reserves the right to amend, rescind, or discontinue this program at
any time without notification.
* Offer good only in the US and Puerto Rico.
* Patient must be a resident of the US or Puerto Rico.
* Prescription must be provided by a healthcare provider licensed in the US or
Puerto Rico.
* Patient must be treated in the outpatient setting of care.
* Additional eligibility criteria may apply. Contact XELSOURCE for details.
INTERIM CARE Rx PROGRAM TERMS & CONDITIONS
* Interim Care Rx is not health insurance and is available for eligible,
commercially insured patients only.
* Offer is only available to patients who have been diagnosed with an
FDA-approved indication for XELJANZ.
* No claim for reimbursement for product dispensed pursuant to this offer may
be submitted to any third-party payer.
* Not available to patients covered under government plans such as Medicaid,
Medicare or other federal or state healthcare programs, including any state
prescription drug assistance programs and the Government Health Insurance
Plan or for residents of Massachusetts, Michigan, Minnesota, Missouri, Ohio,
or Rhode Island.
* Available in 30-day supply. Refills are subject to limitations.
* Interim Care Rx offer does not require, nor will be made contingent on,
purchase requirements of any kind.
* Pfizer reserves the right to amend, rescind, or discontinue this program at
any time without notification.
* Interim Care Rx can only be dispensed by the exclusive pharmacy and only
after benefits investigation has been completed and a delay occurs in the
prior authorization or appeals process.
* Offer good only in the U.S. and Puerto Rico.
* Prescription must be provided by a healthcare provider licensed in the U.S.
or Puerto Rico.
* Continued eligibility for the program requires the submission of two appeals
within 180 days of enrollment. After 12 months of program enrollment an
updated prescription and benefits investigation is required to confirm
continued eligibility.
* The Interim Care Rx Program is applicable to all XELJANZ formulations.
* Additional eligibility criteria may apply. Contact XELSOURCE for details.
VOUCHER TERMS AND CONDITIONS
By redeeming this voucher, you acknowledge that you currently meet the
eligibility criteria and will comply with the terms & conditions described
below:
* You will receive a one-time, 30-day supply of XELJANZ.
* Only new patients may use this voucher. By redeeming this voucher, you
certify that you are not currently using XELJANZ.
* An original voucher and a valid prescription must be presented to the
pharmacy.
* The voucher will be accepted only at participating pharmacies.*
* You must not submit any claim for reimbursement for product dispensed
pursuant to this voucher to any third-party payor, including Medicare,
Medicaid, or any other federal or state health care program. You cannot apply
the value of the free product received through this voucher toward any
government insurance benefit out-of-pocket spending calculations, such as
Medicare Part D True Out-of-Pocket Costs (TrOOP).
* This voucher is not valid where prohibited by law.
* This voucher cannot be combined with any other savings, free trial or similar
offer for the specified prescription. This voucher should not be combined
with samples for the specified prescription.
* This free trial voucher is not health insurance. This free trial voucher is
not intended to address delays or gaps in health insurance coverage for the
specified prescription.
* Offer good only in the U.S. and Puerto Rico.
* No purchase is necessary.
* Patients have no obligation to continue to use XELJANZ.
* Pfizer reserves the right to rescind, revoke, or amend this offer without
notice.
* The voucher is applicable to all XELJANZ formulations.
* This voucher expires 12/31/2022.
*MA residents may select their pharmacy. Otherwise, this free trial will be
supplied through XELSOURCE.
CO-PAY CARD TERMS AND CONDITIONS
By using the XELJANZ Co-Pay Savings Card (the “Card”), you acknowledge that you
currently meet the eligibility criteria and will comply with the terms and
conditions described below:
* Patients are not eligible to use the Card if they are enrolled in a state- or
federally funded insurance program, including but not limited to Medicare,
Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug
assistance program, or the Government Health Insurance Plan available in
Puerto Rico (formerly known as “La Reforma de Salud”).
* Patient must have private insurance. Offer is not valid for cash-paying
patients.
* You will receive a maximum benefit of $6,000–$15,000 per calendar year, which
is defined by the date of enrollment through December 31st of the enrollment
year. After a maximum is reached, you will be responsible for paying the
remaining monthly out-of-pocket costs
* This Card is not valid when the entire cost of your prescription drug is
eligible to be reimbursed by your private insurance plan or other private
health or pharmacy benefit programs.
* You must deduct the value of this Card from any reimbursement request
submitted to your private insurance plan, either directly by you or on your
behalf.
* You are responsible for reporting use of the Card to any private insurer,
health plan, or other third party who pays for or reimburses any part of the
prescription filled using the Card, as may be required. You should not use
the Card if your insurer or health plan prohibits use of manufacturer Cards.
* The Card is not valid where prohibited by law.
* The Card cannot be combined with any other savings, free trial, or similar
offer for the specified prescription.
* The Card will be accepted only at participating pharmacies.
* If your pharmacy does not participate, you may be able to submit a request
for a rebate in connection with this offer.
* The Card is not health insurance.
* Offer good only in the U.S. and Puerto Rico.
* The Card is limited to 1 per person during this offering period and is not
transferable.
* The Card may not be redeemed more than once per 30 days per patient.
* No other purchase is necessary.
* Data related to your redemption of the Card may be collected, analyzed, and
shared with Pfizer, for market research and other purposes related to
assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and
de-identified; it will be combined with data related to other Card
redemptions and will not identify you.
* Pfizer reserves the right to rescind, revoke, or amend the program without
notice.
* The Card is applicable to all XELJANZ formulations.
* Card and Program expires 12/31/2022.
XSAVINGS MOBILE TEXT PROGRAM TERMS & CONDITIONS
User texts "XPROGRAM" to short code 50336.
Text HELP for help, STOP to opt out.
Patients may receive up to 10 messages per month.
Message and data rates may apply.
1. By opting into the XSAVINGS mobile texting program (Program), you consent
to receive up to 10 text messages and/or push notifications from Pfizer
Inc. Such messages may be marketing or non-marketing messages and may
include co-pay related information, fill confirmation, website information,
etc. Messages may be delayed or undelivered for various factors. TrialCard,
carriers (including, but not limited to, T-Mobile) and any service
providers utilized by TrialCard to send messages are not liable for delayed
or undelivered messages.
2. To stop receiving text messages, text STOP to 50336. DOING SO WILL ONLY OPT
YOU OUT OF THIS PROGRAM; you will remain opted in to any other Pfizer Inc.
text message program(s) into which you opted separately.
3. To request more information or to obtain help, text HELP to 50336. You can
also call customer service at 1-844-935-5269.
4. You represent that you are the account holder for the mobile telephone
number(s) that you provide to opt into the Program. You are responsible for
notifying Pfizer Inc. immediately if you change your mobile telephone
number. You may notify Pfizer Inc. of a number change by calling
1-844-935-5269.
5. Message and data rates may apply to each text message sent or received in
connection with the texting program, as provided in your mobile telephone
service rate plan (please contact your mobile telephone carrier for pricing
plans). Applicable roaming charges may apply. Charges are both billed and
payable to your mobile service provider or deducted from your prepaid
account. Pfizer Inc. does not impose a separate fee for sending text
messages.
6. Data obtained from you in connection with this Program may include your
telephone number, your carrier's name, and details of the message (date,
time, and content). Pfizer Inc. may use this information to contact you and
to provide the services you request.
7. For information on data collection and use, please read our full corporate
Privacy Policy, which is incorporated by reference into these Terms.
8. Pfizer Inc. will not be liable for any delays in the receipt of any SMS
messages, as delivery is subject to effective transmission from your
network operator.
9. This Program is available only on these US participating mobile carriers:
Verizon Wireless, Sprint, Boost Mobile, T-Mobile, AT&T, Atlantic
Tele-Network International (ATNI), Alaska Communications Systems (ACS),
ASTAC, Bandwidth.com (includes Republic Wireless), Blue Wireless, Bluegrass
Cellular, Breakaway Wireless, Brightlink, C Spire Wireless (aka Cellular
South), Carolina West Wireless, CellCom, Cellone Nation, Cellular One of
N.E. Arizona, Chariton Valley Cellular, Chat Mobility, Copper Valley
Telecom, Cordova Wireless, Cross Wireless, CTC, Custer Telephone, East
Kentucky Network (Appalachian Wireless), Enflick, GCI Communications,
Google Voice, Illinois Valley Cellular, Inland Cellular, Inteliquent,
iWireless, Leaco Rural Telephone Cooperative, Limitless Mobile, Mid-Rivers
Communications, MobileNation/SI Wireless, MTA Wireless/Matanuska Kenai,
Nemont CDMA, Nemont US UMTS, NewCore Wireless, Nex-Tech Wireless, NNTC
Wireless, Northwest Missouri Cellular, Pine Belt Wireless, Pine Cellular,
Pioneer Cellular, PTCI, Shelcomm, Silver Star PCS, Snake River PCS,
SouthernLINC, SouthernLINC LTE, SRT, STRATA Networks, Standing Rock (SRTI),
Thumb Cellular, Triangle Wireless, Union Wireless, U.S. Cellular, United
Wireless, Viaero Wireless, Virgin Mobile, West Central Wireless.
10. You agree to indemnify Pfizer Inc. and any third parties texting on its
behalf in full for all claims, expenses, and damages related to or caused,
in whole or in part, by your failure to immediately notify us if you change
your telephone number, including but not limited to all claims, expenses,
and damages related to or arising under the Telephone Consumer Protection
Act.
11. Pfizer Inc. may immediately suspend or terminate your participation in the
Program if it believes you are in breach of these SMS Terms and Conditions.
Your participation in this Program is also subject to termination in the
event that your mobile telephone service terminates or lapses. Pfizer Inc.
reserves the right to modify or discontinue, temporarily or permanently,
all or any part of the Program, with or without notice.
12. Pfizer Inc. may revise, modify, or amend these SMS Terms and Conditions at
any time. Any such revision, modification, or amendment shall take effect
when it is posted to Pfizer Inc.'s website. You agree to review these SMS
Terms and Conditions periodically to ensure that you are aware of any
changes. Your continued consent to receive text messages will indicate your
acceptance of those changes.
If you have questions or are in need of additional support, call 1-844-935-5269
or visit www.XELJANZ.com.
INDICATIONS
XELJANZ/XELJANZ XR (tofacitinib) is used to treat adults who have tried TNF
blockers with:
* Moderately to severely active rheumatoid arthritis when 1 or more medicines
called tumor necrosis factor (TNF) blockers have been used, and did not work
well or cannot be tolerated
* Active psoriatic arthritis when 1 or more tumor necrosis factor (TNF) blocker
medicines have been used, and did not work well or cannot be tolerated
* Moderately to severely active ulcerative colitis when 1 or more tumor
necrosis factor (TNF) blocker medicines have been used, and did not work well
or cannot be tolerated
XELJANZ/XELJANZ Oral Solution is used to treat patients 2 years of age and older
with:
* Active polyarticular course juvenile arthritis when 1 or more tumor necrosis
factor (TNF) blocker medicines have been used, and did not work well or
cannot be tolerated
It is not known if XELJANZ/XELJANZ XR is safe and effective in people with
Hepatitis B or C.
XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended for people with
severe liver problems.
It is not known if XELJANZ/XELJANZ Oral Solution is safe and effective in
children for treatment other than active polyarticular course juvenile
arthritis.
It is not known if XELJANZ XR is safe and effective in children.
IMPORTANT SAFETY INFORMATION
The safety information below applies to all marketed formulations of XELJANZ.
Specific risks associated with certain dosing are noted.
Serious infections. XELJANZ can lower the ability of your immune system to fight
infections. Do not start taking XELJANZ if you have any kind of infection unless
your healthcare provider tells you it is okay. Serious infections have happened
in people taking XELJANZ. These serious infections include tuberculosis (TB) and
infections caused by bacteria, fungi, or viruses that can spread throughout the
body. Some people have died from these infections. Your healthcare provider
should test you for TB before starting and during treatment with XELJANZ. You
should not start taking XELJANZ if you have any kind of infection unless your
healthcare professional tells you it is okay.
Before and after starting XELJANZ, tell your doctor if you have an infection or
symptoms of an infection, including:
* fever, sweating, or chills
* cough
* blood in phlegm
* warm, red, or painful skin or sores on your body
* burning when you urinate
* urinating more often than normal
* muscle aches
* shortness of breath
* weight loss
* diarrhea or stomach pain
* feeling very tired
Increased risk of death in people 50 years of age and older who have at least 1
heart disease (cardiovascular) risk factor and are taking XELJANZ 5 mg twice
daily or XELJANZ 10 mg twice daily.
Cancer. XELJANZ may increase your risk of certain cancers by changing the way
your immune system works. Lymphoma and other cancers, including skin cancers,
can happen. People taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily
have a higher risk of certain cancers including lymphoma and lung cancer,
especially if you are a current or past smoker. Tell your healthcare provider if
you have ever had any type of cancer.
Higher dose. People with ulcerative colitis taking the higher dose of XELJANZ
(10 mg twice daily) or XELJANZ XR (22 mg one time each day) have a higher risk
of serious infections, shingles, or skin cancers.
Immune system problem. Some people who have taken XELJANZ with certain other
medicines to prevent kidney transplant rejection have had a problem with certain
white blood cells growing out of control (Epstein Barr Virus–associated
post-transplant lymphoproliferative disorder).
Increased risk of major cardiovascular events such as heart attack, stroke or
death in people 50 years of age and older who have at least 1 heart disease
(cardiovascular) risk factor and are taking XELJANZ 5 mg twice daily or
XELJANZ 10 mg twice daily, especially if you are a current or past smoker.
Get emergency help right away if you have any symptoms of a heart attack or
stroke while taking XELJANZ, including:
* discomfort in the center of your chest that lasts for more than a few
minutes, or that goes away and comes back
* severe tightness, pain, pressure, or heaviness in your chest, throat, neck,
or jaw
* pain or discomfort in your arms, back, neck, jaw, or stomach
* shortness of breath with or without chest discomfort
* breaking out in a cold sweat
* nausea or vomiting
* feeling lightheaded
* weakness in one part or on one side of your body
* slurred speech
Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein
thrombosis, DVT), and arteries (arterial thrombosis) have happened more often in
patients who are 50 years of age and older and with at least 1 heart disease
(cardiovascular) risk factor taking XELJANZ 5 mg twice daily or XELJANZ 10 mg
twice daily. Blood clots in the lungs have also happened in patients with
ulcerative colitis. Some people have died from these blood clots.
* Stop taking XELJANZ and tell your healthcare provider right away if you have
any signs and symptoms of blood clots such as sudden shortness of breath,
difficulty breathing, chest pain, swelling of a leg or arm, leg pain or
tenderness, or red or discolored skin in the leg or arm.
Tears (perforation) in the stomach or intestines. Tell your healthcare provider
if you have had diverticulitis (inflammation in parts of the large intestine) or
ulcers in your stomach or intestines. Some people taking XELJANZ can get tears
in their stomach or intestine. This happens most often in people who also take
nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate.
Tell your healthcare provider right away if you have fever, stomach-area pain
that does not go away, and a change in your bowel habits.
Serious allergic reactions can occur. Stop using XELJANZ and call your
healthcare provider right away if you have swelling of your lips, tongue,
throat, or get hives.
Changes in certain lab test results. Your doctor should do blood tests to check
your white and red blood cells before and while you are taking XELJANZ. Your
doctor should also check certain liver tests. You should not receive XELJANZ if
your lymphocyte count, neutrophil count, or red blood cell count is too low or
your liver function test levels are too high. Changes in lab test results may
cause your healthcare provider to stop your XELJANZ treatment for a time. Your
cholesterol levels should be checked 4 to 8 weeks after you start receiving
XELJANZ.
Before you use XELJANZ, tell your healthcare provider if you:
* Are being treated for an infection, have an infection that won’t go away or
keeps coming back, or think you have symptoms of an infection
* Have TB, or have been in close contact with someone with TB, or were born in,
lived in, or traveled where there is more risk for getting TB
* Have diabetes, chronic lung disease, HIV, or a weak immune system. People
with these conditions have a higher chance for infections
* Live or have lived in certain areas (such as Ohio and Mississippi River
Valleys and the Southwest) where there is an increased chance for getting
certain kinds of fungal infections
* Have or have had Hepatitis B or C
* Are a current or past smoker
* Have had any type of cancer
* Have had a heart attack, other heart problems or stroke
* Have had blood clots
* Have liver or kidney problems
* Have any stomach area (abdominal) pain or been diagnosed with diverticulitis
or ulcers in your stomach or intestines
* Have recently received or plan to receive a vaccine. People taking XELJANZ
should not receive live vaccines but can receive non-live vaccines
* Are pregnant, planning to become pregnant, breastfeeding, or planning to
breastfeed. You should not take XELJANZ and breastfeed
* Have had a reaction to tofacitinib or any of the ingredients
* Are taking other medicines, including prescription and over-the-counter
medicines, vitamins, and herbal supplements. Especially tell your healthcare
provider if you take any of the following medicines while taking XELJANZ
since this may increase your risk of infection:
* tocilizumab (Actemra®)
* etanercept (Enbrel®)
* adalimumab (Humira®)
* infliximab (Remicade®)
* rituximab (Rituxan®)
* abatacept (Orencia®)
* anakinra (Kineret®)
* certolizumab (Cimzia®)
* golimumab (Simponi®)
* ustekinumab (Stelara®)
* secukinumab (Cosentyx®)
* vedolizumab (Entyvio®)
* sarilumab (Kevzara®)
* azathioprine, cyclosporine, or other immunosuppressive drugs
* Tell your healthcare provider if you are taking medicines that affect the way
certain liver enzymes work. Ask your healthcare provider if you are not sure
if your medicine is one of these.
What are other possible side effects of XELJANZ/XELJANZ XR?
If you are a carrier of the Hepatitis B or C virus (viruses that affect the
liver), the virus may become active while you use XELJANZ. Your healthcare
provider may do blood tests before starting and while using treatment with
XELJANZ. Tell your healthcare provider if you have any signs of these symptoms:
feel very tired, little or no appetite, clay-colored bowel movements, chills,
muscle aches, skin rash, skin or eyes look yellow, vomiting, fevers, stomach
discomfort, or dark urine.
Common side effects in adults with rheumatoid arthritis and psoriatic arthritis
include upper respiratory tract infections (common cold, sinus infections),
headache, diarrhea, nasal congestion, sore throat, runny nose (nasopharyngitis),
and high blood pressure (hypertension).
Common side effects in adults with ulcerative colitis include nasal congestion,
sore throat, runny nose (nasopharyngitis), increased cholesterol levels,
headache, upper respiratory tract infections (common cold, sinus infections),
increased muscle enzyme levels, rash, diarrhea, and shingles (herpes zoster).
Common side effects in children (2 & older) with polyarticular course juvenile
arthritis include upper respiratory tract infections (common cold, sinus
infections), nasal congestion, sore throat, and runny nose (nasopharyngitis),
headache, fever, nausea, and vomiting.
XELJANZ & Pregnancy
XELJANZ may affect the ability of females to get pregnant. It is not known if
this will change after stopping XELJANZ. It is not known if XELJANZ will harm an
unborn baby.
* Pregnancy Registry: Pfizer has a registry for pregnant women who take
XELJANZ. The purpose of this registry is to check the health of the pregnant
mother and her baby. If you are pregnant or become pregnant while taking
XELJANZ, talk to your healthcare provider about how you can join this
pregnancy registry or you may contact the registry at 1-877-311-8972 to
enroll.
You and your healthcare provider should decide if you will take XELJANZ or
breastfeed. You should not do both. After you stop your treatment with XELJANZ
do not start breastfeeding again until 18 hours after your last dose of XELJANZ
or 36 hours after your last dose of XELJANZ XR.
Please see full Prescribing Information, including BOXED WARNING and Medication
Guide.
March 2022
S
M
T
W
T
F
S
27
28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
March 2022
S
M
T
W
T
F
S
27
28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
March 2022
S
M
T
W
T
F
S
27
28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
March 2022
S
M
T
W
T
F
S
27
28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
March 2022
S
M
T
W
T
F
S
27
28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
March 2022
S
M
T
W
T
F
S
27
28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
March 2022
S
M
T
W
T
F
S
27
28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2